Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Pediatr Infect Dis J. 2022 Jun 7;41(7):556–562. doi: 10.1097/INF.0000000000003559

Table 1:

Participant Population

Population Solithromycin
(n=70)
Comparator
(n=24)
Age in years, mean (SD) 9.5 (4.7) 9.7 (5.0)
Female sex, n (%) 30 (42.9) 11 (45.8)
Race, n (%)
 Black or African American 11 (15.7) 2 (8.3)
 White 47 (67.1) 16 (66.7)
 Asian 12 (17.1) 4 (16.7)
 Other 0 (0) 2 (8.3)
Hispanic/Latino ethnicity, n (%) 2 (2.9) 2 (8.3)
Medical history at enrollment
 Asthma 12 (17.1) 3 (12.5)
 Allergic disease 5 (7.1) 2 (8.3)
 Tracheomalacia 1 (1.4) 0 (0)
 ADHD 0 (0) 0 (0)
 Restrictive Lung Disease 0 (0) 1 (4.2)
 GERD 3 (4.3) 0 (0)
Region of enrollment, n (%)
 Bulgaria 21 (30) 6 (25)
 Hungary 19 (27.1) 4 (16.7)
 Philippines 12 (17.1) 4 (16.7)
 Spain 0 (0) 1 (4.2)
 United States 18 (25.7) 9 (37.5)

SD - standard deviation, ADHD – attention deficit/hyperactivity disorder, GERD – gastroesophageal reflux disease